TGFB1 and neoplasm: Bintrafusp alfa (M7824), targeting both PD-L1 and TGF-β, has shown efficacy in inhibiting tumor mesenchymalization, reducing PD-L1-dependent immunosuppression, and overcoming chemoresistance in NSCLC (80).